The Chart of the Day belongs to Dermira (Nasdaq:DERM). I found the dermatology products stock by using Barchart to sort today's All Time High list for the stocks with the highest Weighted Alpha then sorted for the stocks with at least an 80% or better technical buying signals. I then used the Flipchart feature to review the Charts. Since the Trend Spotter signaled a buy on 6/1 the stock gained 73.87%.

Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California.

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 100% Barchart technical buy signals
• 100.90+ Weighted Alpha
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 9 new highs and up 48.30% in the last month
• Relative Strength Index 78.83%
• Barchart computes a technical support level at 23.69
• Recently traded at 26.90 with a 50 day moving average of 19.28

Fundamental factors:

• Market Cap $661.74 million
• New so not closely followed
• Has had 2 great earnings surprises
• Earnings estimated to increase 35.90% this year ad an additional 10.70% next year
• Wall Street analysts issued 2 strong buy and another buy recommendation
• Only 1 individual investor on Motley Fool follows the stock and they have an Outperform opinion

The Trend Spotter has been a good technical trading strategy or this stock and should be used for now.